Keyphrases
Breast Cancer Cells
100%
ErbB3
100%
Protein Level
100%
MRNA Level
100%
Gefitinib
100%
Epidermal Growth Factor Receptor Inhibitors
57%
ErbB2
57%
ErbB Receptors
42%
Epidermal Growth Factor Receptor
28%
Downregulated Genes
28%
Tyrosine Kinase Inhibitor
14%
Receptor Targets
14%
Anticancer Drugs
14%
In Cancer
14%
General Affect
14%
Topoisomerase IIα
14%
Ki-67
14%
Targeted Drugs
14%
Gene Expression
14%
Family Members
14%
Breast Cancer
14%
Inhibitor Treatment
14%
Overexpressing
14%
Cell Proliferation
14%
Cancer Therapy
14%
Common Genes
14%
Apoptotic Pathway
14%
Cyclin
14%
Cancer Treatment
14%
Potential Gains
14%
Cell Survival
14%
Delocalization
14%
Clinical Effect
14%
Intensive Development
14%
Expression Level
14%
Medicine and Dentistry
Cancer Cell
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Messenger RNA
100%
Gefitinib
100%
Breast Cancer
100%
Epidermal Growth Factor Receptor
71%
Cancer Therapy
28%
Gene Expression
14%
DNA Topoisomerase (ATP Hydrolysing)
14%
Tyrosine-Kinase Inhibitor
14%
Anticarcinogen
14%
Cell Proliferation
14%
Receptor Family
14%
Cell Survival
14%
Cyclin
14%
Drug Delivery System
14%
Pharmacology, Toxicology and Pharmaceutical Science
Gefitinib
100%
Messenger RNA
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
100%
Breast Cancer
100%
Epidermal Growth Factor Receptor
71%
Malignant Neoplasm
28%
Anticarcinogen
14%
Cycline
14%
DNA Topoisomerase (ATP Hydrolysing)
14%
Protein Tyrosine Kinase Inhibitor
14%
Drug Delivery System
14%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Messenger RNA
100%
Epidermal Growth Factor Receptor
100%
Gefitinib
70%
Growth Factor Receptor Inhibitor
40%
Tyrosine Kinase Inhibitor
10%
DNA Gyrase
10%
Gene Expression
10%
Drug Targeting
10%
Cyclin
10%
Cell Survival
10%
Anticancer
10%
Cell Proliferation
10%